Skip to main content

Protocol G

Type:
Prevalence / cross-sectional
Study Status:
Ongoing
Enrollment Status:
Varies across multiple sites
Countries:
Uganda;Zambia;Rwanda;South Africa;Kenya;India;Thailand;Nigeria;Australia;United Kingdom;USA;Ivory Coast
Partners:
Uganda Virus Research Institute-International AIDS Vaccine Initiative (UVRI-IAVI)-Entebbe, Uganda; Zambia-Emory Research Project (ZEHRP)-Lusaka, Zambia; Projet San Francisco (PSF-Kigali)-Kigali, Rwanda; Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH), Nairobi, Kenya; YRG Care, Chennai, India; Vaccine Trial Centre, Mahidol University, Bangkok, Thailand; Centre de Diagnostic et de Recherche sur le SIDA et les infections opportunistes (CeDReS), CHU Treichville, BP V3, Abidjan, Côte d’Ivoire; Institute of Human Virology (IHV), Nigeria; National Serology Reference Laboratory (NRL), Australia; St. Stephen’s Centre, London, UK; SUNY Downstate Medical Center, Brooklyn, NY; AFRIMS (Armed Forces Research Institute of Medical Sciences), Bangkok, Thailand.

 
Study Summary:
 
To generate broadly neutralizing monoclonal antibodies (mAbs) from volunteers who are HIV infected and have broadly cross-reactive serum neutralizing activity.